Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017

World News: . []

NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (OTCQX:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that preclinical data on its anti-PD-L1 antibody and EGFR inhibitor programs will be presented in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2017, to be held April 1-5, at the Walter E. Washington Convention Center in Washington, D.C.

Details on the poster presentations are as follows:

For additional information, please visit the AACR website: .

Jaclyn Jaffe
Checkpoint Therapeutics, Inc.

Fortress Biotech Media Relations
Laura Bagby
6 Degrees
(312) 448-8098;

More news and information about Checkpoint Therapeutics, Inc

Published By:

Globe Newswire: 12:00 GMT Monday 20th March 2017

Published: .

Search for other references to "checkpoint" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers